RE:RE:Competition.Rube, I saw the "no late stage competition" just like everyone else. HS-401 is probably a typo on Telesta's part. They named it Vesigenurtacel-L in the presentation, which is in fact HS-410 (see link https://www.heatbio.com/product-pipeline/hs-410) and also matches the clinical.gov identifier. Maybe I should email Don Olds like you suggested to let him know there is a typo in his presentation (snarky much?). They certainly haven't missed it and are aware of it, but they rightly chose not to showcase it in their investor presentation. What officer in their right mind would? They can get away with not naming it a late stage competitor because it has only finished stage II. However the fast track designation today and the fact that stage II DFS are greater than MCNA certainly makes it a possible mid term competitor. In an industry where valueation is based on 10 to over 100 times future earnings, a 3-5 year competition free run versus a 10-15 year run certainly matters to both long term price targets if they go alone, and to buyers who are looking now. Listen, I'm not saying that the stock is worth less than it is priced at now or that it won't go up, it will unless there are major piss-ups, but those investors trying to value it should know that there is in fact competition following and I've seen some very optimistic valuations here. The other question we should be asking is, since MCNA is so comparable, where are it's FDA Fast Track designation and Breakthrough Therapy Designation?